AB5334P
Anti-Synuclein α Antibody
Chemicon®, from sheep
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Recommended Products
biological source
sheep
Quality Level
antibody form
affinity purified immunoglobulin
antibody product type
primary antibodies
clone
polyclonal
purified by
affinity chromatography
species reactivity
rat, human
manufacturer/tradename
Chemicon®
technique(s)
immunohistochemistry: suitable (paraffin)
western blot: suitable
NCBI accession no.
UniProt accession no.
shipped in
dry ice
target post-translational modification
unmodified
Gene Information
human ... SNCA(6622)
Specificity
Recognizes alpha synuclein.
Immunogen
Synthetic peptide corresponding amino acids 116-131 of human alpha synuclein.
Application
Detect Synuclein using this Anti-Synuclein Antibody, α validated for use in WB, IH(P).
Immunohistochemistry: 0.5-1 μg/mL on frozen or paraffin sections.
Western blot: 0.5-1 μg/mL
Optimal working dilutions must be determined by the end user.
Western blot: 0.5-1 μg/mL
Optimal working dilutions must be determined by the end user.
Research Category
Neuroscience
Neuroscience
Research Sub Category
Neurodegenerative Diseases
Neurodegenerative Diseases
Linkage
Replaces: 04-1053
Physical form
Affinity purified immunoglobulin in PBS containing 0.02% sodium azide. Lyophilized. Reconstitute with 50 μL of sterile distilled water. Centrifuge to remove any residue. Glycerol (1:1) can be added for additional stability.
Storage and Stability
Maintain lyophilized material at -70°C (dry) for up to 12 months. After reconstitution maintain at -20°C in undiluted aliquots for up to 6 months. Avoid repeated freeze/thaw cycles.
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
recommended
Product No.
Description
Pricing
Storage Class
13 - Non Combustible Solids
wgk_germany
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Ivani Brys et al.
The European journal of neuroscience, 46(3), 1906-1917 (2017-04-04)
Parkinson's disease (PD) is a neurodegenerative disorder characterised by progressive motor symptoms resulting from chronic loss of dopaminergic neurons in the nigrostriatal pathway. The over expression of the protein alpha-synuclein in the substantia nigra has been used to induce progressive
Lojze M Smid et al.
Journal of Alzheimer's disease : JAD, 36(2), 261-274 (2013-04-10)
This work is aimed at correlating pre-mortem [18F]FDDNP positron emission tomography (PET) scan results in a patient with dementia with Lewy bodies (DLB), with cortical neuropathology distribution determined postmortem in three physical dimensions in whole brain coronal sections. Analysis of
A highly reproducible rotenone model of Parkinson's disease.
Cannon, JR; Tapias, V; Na, HM; Honick, AS; Drolet, RE; Greenamyre, JT
Neurobiology of Disease null
Yong-Ren Chen et al.
International journal of molecular sciences, 21(11) (2020-05-31)
Parkinson's disease (PD) is a long-term degenerative disease of the central nervous system (CNS) that primarily affects the motor system. So far there is no effective treatment for PD, only some drugs, surgery, and comprehensive treatment can alleviate the symptoms
Edward I Ginns et al.
Molecular genetics and metabolism, 111(2), 152-162 (2014-01-07)
Clinical, epidemiological and experimental studies confirm a connection between the common degenerative movement disorder Parkinson's disease (PD) that affects over 1 million individuals, and Gaucher disease, the most prevalent lysosomal storage disorder. Recently, human imaging studies have implicated impaired striatal
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service